Clinical Trial Detail

NCT ID NCT03289962
Title A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

melanoma

colorectal cancer

Advanced Solid Tumor

triple-receptor negative breast cancer

transitional cell carcinoma

renal cell carcinoma

head and neck squamous cell carcinoma

Therapies

RO7198457

Atezolizumab + RO7198457

Age Groups: adult senior

No variant requirements are available.